Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy
The development and progression of breast cancer are closely linked to estrogen levels. For patients with estrogen receptor-positive breast cancer, endocrine therapy targeting estrogen pathways remains a cornerstone of postoperative treatment. Aromatase, a critical enzyme in estrogen biosynthesis, e...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of International Journal of Geriatrics
2025-01-01
|
| Series: | Guoji laonian yixue zazhi |
| Subjects: | |
| Online Access: | http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.001&lang=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592761498370048 |
|---|---|
| author | Andi Tian Chunyu Zhang |
| author_facet | Andi Tian Chunyu Zhang |
| author_sort | Andi Tian |
| collection | DOAJ |
| description | The development and progression of breast cancer are closely linked to estrogen levels. For patients with estrogen receptor-positive breast cancer, endocrine therapy targeting estrogen pathways remains a cornerstone of postoperative treatment. Aromatase, a critical enzyme in estrogen biosynthesis, exhibits heightened expression in breast tumors and their surrounding tissues. Consequently, aromatase inhibitors (AI) have become widely adopted as a primary endocrine therapy for breast cancer. While AI effectively lower tumor recurrence rates, they are associated with adverse effects such as bone loss, osteoporosis, and increased risk of osteoporotic fractures. These effects are particularly pronounced in elderly breast cancer patients, who are predisposed to accelerated bone mass loss and a higher prevalence of osteoporosis. This review explores the mechanisms of action of AI, the pathways through which they contribute to bone density reduction and osteoporosis, and the risk stratification for osteoporotic fractures. Additionally, it highlights evidence-based strategies for preventing and managing AI-induced osteoporosis in elderly breast cancer patients. By addressing these challenges, the review aims to enhance understanding of the bone health issues faced by this patient population, improve their quality of life, and reduce the incidence of complications. |
| format | Article |
| id | doaj-art-0118c28a271e4bc4a40a13b9bab7c84d |
| institution | Kabale University |
| issn | 1674-7593 |
| language | zho |
| publishDate | 2025-01-01 |
| publisher | Editorial Office of International Journal of Geriatrics |
| record_format | Article |
| series | Guoji laonian yixue zazhi |
| spelling | doaj-art-0118c28a271e4bc4a40a13b9bab7c84d2025-01-21T02:59:39ZzhoEditorial Office of International Journal of GeriatricsGuoji laonian yixue zazhi1674-75932025-01-014611410.3969/j.issn.1674-7593.2025.01.001Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapyAndi Tian0Chunyu Zhang1Department of Geriatrics, the Second Affiliated Hospital of Dalian Medical University, Dalian 116023Department of Geriatrics, the Second Affiliated Hospital of Dalian Medical University, Dalian 116023The development and progression of breast cancer are closely linked to estrogen levels. For patients with estrogen receptor-positive breast cancer, endocrine therapy targeting estrogen pathways remains a cornerstone of postoperative treatment. Aromatase, a critical enzyme in estrogen biosynthesis, exhibits heightened expression in breast tumors and their surrounding tissues. Consequently, aromatase inhibitors (AI) have become widely adopted as a primary endocrine therapy for breast cancer. While AI effectively lower tumor recurrence rates, they are associated with adverse effects such as bone loss, osteoporosis, and increased risk of osteoporotic fractures. These effects are particularly pronounced in elderly breast cancer patients, who are predisposed to accelerated bone mass loss and a higher prevalence of osteoporosis. This review explores the mechanisms of action of AI, the pathways through which they contribute to bone density reduction and osteoporosis, and the risk stratification for osteoporotic fractures. Additionally, it highlights evidence-based strategies for preventing and managing AI-induced osteoporosis in elderly breast cancer patients. By addressing these challenges, the review aims to enhance understanding of the bone health issues faced by this patient population, improve their quality of life, and reduce the incidence of complications.http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.001&lang=enaromatase inhibitorbreast cancerosteoporosis |
| spellingShingle | Andi Tian Chunyu Zhang Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy Guoji laonian yixue zazhi aromatase inhibitor breast cancer osteoporosis |
| title | Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy |
| title_full | Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy |
| title_fullStr | Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy |
| title_full_unstemmed | Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy |
| title_short | Strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy |
| title_sort | strategies for preventing and managing osteoporosis in elderly breast cancer patients undergoing aromatase inhibitor therapy |
| topic | aromatase inhibitor breast cancer osteoporosis |
| url | http://gwll.publish.founderss.cn/thesisDetails#10.3969/j.issn.1674-7593.2025.01.001&lang=en |
| work_keys_str_mv | AT anditian strategiesforpreventingandmanagingosteoporosisinelderlybreastcancerpatientsundergoingaromataseinhibitortherapy AT chunyuzhang strategiesforpreventingandmanagingosteoporosisinelderlybreastcancerpatientsundergoingaromataseinhibitortherapy |